JDD Buzz Series | Skin of Color Representation in Pre-Clerkship Dermatology Curriculum
Medical school dermatology curriculum is known for its lack of representation of images of skin of color. A letter to the editor published in the July Journal of Drugs in Dermatology shows the effects on diagnostic accuracy, perception, and confidence when one medical school took action to make its pre-clerkship dermatology curriculum more diverse.
I interviewed authors Dahyeon (Esther) Kim, a …
Medical school dermatology curriculum is known for its lack of representation of images of skin of color. A letter to the editor published in the July Journal of Drugs in Dermatology shows the effects on diagnostic accuracy, perception, and confidence when one medical school took action to make its pre-clerkship dermatology curriculum more diverse.
I interviewed authors Dahyeon (Esther) Kim, a … 
The July 2025 issue of the Journal of Drugs in Dermatology brings together another outstanding selection of articles, offering cutting-edge insights and real-world strategies across a diverse range of dermatology topics. This month’s editor’s highlights spotlight innovative approaches to photoprotection in melasma and photodamage, emerging non-pharmaceutical solutions for fem … 
Welcome to another installment of our popular “From the JDD Podcast Vault” series! This week, we’re unraveling the fascinating story behind itch management with the episode: From Rags to Itches: The Evolution of Topical and Systemic Options for Pruritus, hosted by the ever-engaging Dr. Adam Friedman.
We all know that urge—“Just scratch it!” But for countless patients, chronic prurit … 
The June 2025 issue of the Journal of Drugs in Dermatology delivers a diverse and thought-provoking selection of studies that place a spotlight on acne and rosacea while spanning the latest innovations and clinical insights across the dermatology spectrum. This month’s editor’s picks feature new approaches to some of the field’s most common—and challenging—conditions, from acne-induced … 
Use of GLP-1 agonists is becoming increasingly more common in the U.S. According to a 2024 poll, one in eight adults has at least tried this medication class. A brief communication published in the June Journal of Drugs in Dermatology shares concerns that could arise when a patient is concurrently on a GLP-1 agonist and isotretinoin.
I interviewed author Travis W. Blalock, MD, FAAD, FACMS, dire … 